Ayunova Pharmaceutical LLP

Darbepoetin Alfa Pre-Filled Syringe (PFS) 100 mcg / 0.5–1 ml

Darbepoetin Alfa PFS is a long-acting erythropoiesis-stimulating agent (ESA) used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, or other conditions causing reduced red blood cell production. This sterile pre-filled syringe ensures accurate dosing, ease of administration, and improved patient compliance. Darbepoetin Alfa has an extended half-life compared to conventional erythropoietin, allowing less frequent dosing while effectively increasing hemoglobin levels.

• Darbepoetin Alfa (Recombinant): 100 mcg

• Excipients: Water for injection, stabilizers, buffer agents, and BP/USP-grade excipients

Each pre-filled syringe delivers 100 mcg in 0.5–1 ml depending on the manufacturer specification.

• Treatment of anemia in chronic kidney disease (CKD) patients

• Management of anemia in cancer patients undergoing chemotherapy

• Prevention of anemia in patients undergoing major surgery

• Treatment of anemia caused by other chronic conditions or bone marrow disorders

• Administered via subcutaneous or intravenous injection

• Dose and frequency determined by physician based on hemoglobin levels and patient condition

• Less frequent dosing required due to extended half-life

• Must be used under professional medical supervision

• Pre-filled syringe for accurate and convenient dosing

• Long-acting erythropoiesis-stimulating agent for fewer injections

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Supports effective red blood cell production and anemia management

• Suitable for hospital, clinic, and home care use

• 0.5–1 ml PFS containing 100 mcg Darbepoetin Alfa

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 DAYS
• Packaging Details: 100mcg/0.5-1ml

Heparin for Injection BP

Heparin for Injection BP is a sterile aqueous preparation of Heparin Sodium, a fast-acting anticoagulant used to prevent and treat thromboembolic disorders. It works by inhibiting clotting factors in the blood, thereby preventing the formation and extension of blood clots.

This injectable formulation is widely used in hospitals and clinical settings during surgery, dialysis, catheterization, and in the management of deep vein thrombosis and pulmonary embolism.

Each mL contains:

• Heparin Sodium BP – 1,000 IU / 5,000 IU / 25,000 IU (strength may vary)

• Water for Injection BP

(Exact strength and volume available as per requirement.)

• Prevention and treatment of deep vein thrombosis (DVT)

• Management of pulmonary embolism

• Anticoagulation during surgery and invasive procedures

• Prevention of clotting in hemodialysis and extracorporeal circulation

• Maintenance of indwelling intravenous catheters and cannulae

• Acute coronary syndromes (as prescribed)

• Administered by intravenous (IV) injection or infusion

• Not for intramuscular use

• Dosage and duration depend on patient condition and coagulation parameters

• To be used strictly under medical supervision

• Glass vials or ampoules

• Available pack sizes: 1 mL / 2 mL / 5 mL / 10 mL

• Bulk hospital supply available

• Store below 25°C

• Protect from light

• Do not freeze

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Typically 24–36 months.

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 5000m

Enoxaparin for Injection BP

Enoxaparin for Injection BP is a sterile preparation of Enoxaparin Sodium, a low molecular weight heparin (LMWH) with anticoagulant activity. It is used for the prevention and treatment of thromboembolic disorders by inhibiting clot formation and reducing the risk of deep vein thrombosis.

Compared to unfractionated heparin, enoxaparin provides more predictable anticoagulant effects, longer duration of action, and requires less frequent monitoring.

Each prefilled syringe / vial contains:

• Enoxaparin Sodium BP –

  • 20 mg (2,000 IU)

  • 40 mg (4,000 IU)

  • 60 mg (6,000 IU)

  • 80 mg (8,000 IU)

  • 100 mg (10,000 IU)

• Water for Injection BP

(Strengths may vary as per requirement.)

• Prevention of deep vein thrombosis (DVT)

• Treatment of DVT with or without pulmonary embolism

• Prevention of thromboembolic complications in orthopedic and general surgery

• Management of acute coronary syndromes (unstable angina, NSTEMI, STEMI)

• Anticoagulation during hemodialysis

• Administered by subcutaneous injection

• IV use only in specific indications under medical supervision

• Dosage depends on patient weight, indication, and renal function

• To be used under strict medical supervision

• Prefilled syringes with safety needle

• Glass vials (where applicable)

• Pack sizes as per strength (single-use packs)

• Bulk and hospital supply available

• Store below 25°C

• Protect from light

• Do not freeze

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Typically 24–36 months

• Manufacturing Standards: WHO-GMP certified

• Usage Area: Hospitals, cardiac centers, dialysis units

• Prescription Status: Prescription drug (Rx)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 20mg

Furosemide for Injection BP

Furosemide for Injection BP is a sterile, parenteral formulation of Furosemide, a potent loop diuretic used to remove excess fluid from the body. It acts on the loop of Henle in the kidneys to increase urine output, making it effective in managing edema associated with heart failure, liver disease, and renal disorders.

It is widely used in hospital and critical care settings, especially in acute pulmonary edema, hypertension emergencies, and fluid overload conditions.

Each mL contains:

• Furosemide BP – 10 mg / 20 mg / 40 mg

• Sodium Hydroxide / Hydrochloric Acid – for pH adjustment

• Water for Injection BP

(Common strengths: 10 mg/mL or 20 mg/mL; exact strength available on request.)

• Management of edema associated with congestive heart failure, liver cirrhosis, and renal disease

• Acute pulmonary edema

• Treatment of hypertensive emergencies

• Fluid overload in critically ill patients

• Adjunct therapy in hypercalcemia

• Administered by intravenous (IV) or intramuscular (IM) injection

• Dosage depends on patient condition, age, and response

• Careful monitoring of electrolytes and renal function recommended

• To be used under medical supervision

• Glass ampoules or vials

• Available pack sizes: 2 mL / 5 mL / 10 mL

• Bulk and hospital supply available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Typically 24–36 months

• Manufacturing Standards: WHO-GMP certified

• Usage Area: Hospitals, ICUs, emergency units

• Prescription Status: Prescription drug (Rx)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 10x1 ml

Dopamine Injection BP

Dopamine For Injection BP is a vasoactive drug used for the management of hypotension, shock, and heart failure. It acts on dopaminergic and adrenergic receptors, providing dose-dependent effects on the cardiovascular system.

• At low doses, it primarily stimulates dopaminergic receptors, promoting renal and mesenteric vasodilation.

• At moderate doses, it stimulates β1-adrenergic receptors, increasing cardiac output and heart rate.

• At high doses, it stimulates α-adrenergic receptors, leading to vasoconstriction and increased blood pressure.

It is commonly used in critical care settings to manage acute hypotension, cardiogenic shock, and poor perfusion states.

Each ml contains:

• Dopamine Hydrochloride BP/USP – 40 mg/ml (adjustable as per formulation)

• Excipients: Sterile water for injection, suitable buffer

• Management of shock (cardiogenic, septic, or distributive)

• Treatment of acute hypotension

• Support in heart failure with low cardiac output

• Enhancement of renal perfusion in select patients

• Administer via intravenous infusion only

• Dose is titrated based on patient response and clinical condition

• Continuous hemodynamic monitoring recommended

• Use under strict medical supervision in ICU or emergency settings

• Vials: 5 ml / 10 ml / 20 ml (concentration: 40 mg/ml)

• Sterile, ready-for-injection formulation

• Box packaging with product information leaflet

• Store at 2–8°C

• Protect from light and freezing

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10x1ml

Enoxaparin Sodium (Low Molecular Weight Heparin) Pre-Filled Syringe 100 mg/1 ml

Enoxaparin Sodium is a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat blood clots. This sterile pre-filled syringe (PFS) formulation ensures accurate dosing and easy administration. Enoxaparin acts by inhibiting clotting factors in the blood, helping prevent deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. It is widely used in surgical, medical, and high-risk patients for effective anticoagulation.

• Enoxaparin Sodium: 100 mg (equivalent to 10,000 IU anti-Xa activity)

• Excipients: Water for injection, sodium chloride, and BP/USP-grade stabilizers

Each prefilled syringe delivers a precise dose of 100 mg in 1 ml.

• Prevention of deep vein thrombosis (DVT) in surgical or immobilized patients

• Treatment of DVT with or without pulmonary embolism (PE)

• Prevention of clot formation in patients with unstable angina or myocardial infarction

• Anticoagulation in high-risk medical patients

• As part of bridging therapy for patients requiring warfarin therapy

• Administered via subcutaneous injection only

• Dosage depends on patient weight, indication, and renal function

• Use under the supervision of a qualified healthcare professional

• Do not use intravenous injection unless specifically prescribed

• Pre-filled syringe ensures accurate, ready-to-use dosing

• Sterile and pyrogen-free formulation

• Low molecular weight heparin with predictable anticoagulant response

• BP/USP-compliant quality

• 1 ml PFS containing 100 mg enoxaparin

• Available in individual blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 100mg/1ml

Heparin (PFS) 10,000 IU / 1 ml

Heparin Sodium is a widely used anticoagulant that prevents blood clot formation by inhibiting thrombin and other clotting factors. This sterile pre-filled syringe (PFS) formulation ensures precise dosing and convenient administration for hospital and clinical use. Heparin is indicated for prophylaxis and treatment of thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and for anticoagulation in surgical and high-risk medical patients.

• Heparin Sodium: 10,000 IU

• Excipients: Water for injection, sodium chloride, and BP/USP-grade stabilizers

Each pre-filled syringe delivers a precise 10,000 IU dose in 1 ml.

• Prevention of deep vein thrombosis (DVT) in surgical and immobile patients

• Treatment of DVT and pulmonary embolism (PE)

• Anticoagulation during extracorporeal circulation (e.g., dialysis)

• Prevention of clot formation in high-risk medical patients

• Management of unstable angina and myocardial infarction in specific cases

• Administered via intravenous or subcutaneous injection as per clinical requirement

• Dosage depends on patient condition, weight, and medical indication

• Must be used under the supervision of a qualified healthcare professional

• Pre-filled syringe ensures accurate, ready-to-use dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Widely used anticoagulant with predictable effect

• Convenient packaging suitable for hospital and clinical use

• 1 ml PFS containing 10,000 IU heparin

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Protect from light and moisture

• Keep out of reach of children

• Do not freeze

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1ml

Atorvastatin Tablets BP – 40 mg

Atorvastatin Tablets BP is an oral lipid-lowering agent belonging to the statin (HMG-CoA reductase inhibitor) class, used for the management of hypercholesterolemia and dyslipidemia.

It works by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, which leads to reduction of LDL cholesterol, total cholesterol, and triglycerides while increasing HDL cholesterol.

Atorvastatin is widely prescribed for primary and secondary prevention of cardiovascular diseases, including heart attacks, stroke, and atherosclerosis, especially in patients with elevated cholesterol levels or high cardiovascular risk.

Each film-coated tablet contains:

• Atorvastatin Calcium BP – 40 mg (equivalent to Atorvastatin 40 mg)

• Excipients: q.s.

• Hypercholesterolemia

• Mixed dyslipidemia

• Familial hypercholesterolemia

• Primary and secondary prevention of cardiovascular events

• Atherosclerotic cardiovascular disease (ASCVD) risk reduction

• High triglyceride management

• Adjunct to diet and lifestyle changes in lipid disorders

• Route: Oral

• Usual Dose: 10–80 mg once daily, adjusted by physician based on lipid levels and patient response

• Administration: Take any time of the day, with or without food

⚠ Monitor liver function tests regularly
⚠ Avoid in active liver disease or pregnancy
⚠ Caution in patients with renal impairment

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Amlodipine Tablets BP – 10 mg

Amlodipine Tablets BP is an oral antihypertensive agent belonging to the dihydropyridine class of calcium channel blockers. It works by relaxing vascular smooth muscles, causing dilation of arteries and arterioles, which helps to reduce blood pressure and improve blood flow.

Amlodipine is widely used for management of hypertension, angina pectoris, and coronary artery disease, and is often prescribed as monotherapy or in combination with other antihypertensives.

Each film-coated tablet contains:

• Amlodipine Besylate BP – 10 mg (equivalent to Amlodipine 10 mg)

• Excipients: q.s.

• Hypertension (high blood pressure)

• Chronic stable angina

• Vasospastic (Prinzmetal’s) angina

• Combination therapy in resistant hypertension

• Coronary artery disease management

• Off-label use in certain pediatric and elderly populations (as directed by physician)

• Route: Oral

• Usual Dose: 5–10 mg once daily, adjusted according to blood pressure response

• Administration: Can be taken with or without food

⚠ Monitor blood pressure regularly
⚠ Caution in patients with severe hypotension, heart failure, or liver impairment
⚠ Avoid abrupt discontinuation

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Telmisartan Tablets BP – 80 mg

Telmisartan Tablets BP is an oral antihypertensive agent belonging to the Angiotensin II Receptor Blocker (ARB) class. It works by blocking angiotensin II receptors, which leads to vasodilation, reduced blood pressure, and decreased cardiac workload.

Telmisartan is widely used for the management of hypertension, cardiovascular risk reduction, and renal protection in diabetic patients. It can be prescribed as monotherapy or in combination with other antihypertensive agents for optimal blood pressure control.

Each film-coated tablet contains:

• Telmisartan BP – 80 mg

• Excipients: q.s.

• Hypertension (high blood pressure)

• Reduction of cardiovascular risk in patients at high risk of heart attack or stroke

• Renal protection in type 2 diabetic patients with proteinuria

• Left ventricular hypertrophy risk reduction

• Heart failure management (as adjunct therapy)

• Combination therapy for resistant hypertension

• Route: Oral

• Usual Dose: 40–80 mg once daily, adjusted by physician based on blood pressure response

• Administration: Can be taken with or without food

⚠ Monitor renal function and serum potassium levels regularly
⚠ Caution in patients with hepatic impairment
⚠ Avoid in pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Atorvastatin + Ezetimibe Tablets BP – 10 mg + 10 mg

Atorvastatin + Ezetimibe Tablets BP is an oral lipid-lowering combination therapy used for the management of hypercholesterolemia and mixed dyslipidemia.

• Atorvastatin (10 mg): A HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, lowering LDL-C, total cholesterol, and triglycerides, and moderately increasing HDL-C.

• Ezetimibe (10 mg): A cholesterol absorption inhibitor that reduces intestinal absorption of dietary and biliary cholesterol, enhancing the LDL-lowering effect of atorvastatin.

This combination provides synergistic lipid-lowering effects, making it ideal for patients not adequately controlled with statin monotherapy, helping reduce cardiovascular risk.

Each film-coated tablet contains:

• Atorvastatin Calcium BP – 10 mg

• Ezetimibe BP – 10 mg

• Excipients: q.s.

• Primary hypercholesterolemia (heterozygous familial or non-familial)

• Mixed dyslipidemia

• Patients with insufficient LDL-C control on statin monotherapy

• Reduction of cardiovascular morbidity and mortality in high-risk patients

• Adjunct therapy in combination with diet and lifestyle modifications

• Management of hyperlipidemia in patients intolerant to high-dose statin therapy

• Route: Oral

• Usual Dose: 1 tablet once daily, or as prescribed by the physician

• Administration: Take with or without food, preferably at the same time each day

⚠ Monitor liver function, lipid profile, and muscle-related side effects regularly
⚠ Contraindicated in active liver disease or pregnancy
⚠ Use caution in patients with a history of myopathy or rhabdomyolysis

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

MILICOR Injection contains Milrinone Lactate, a phosphodiesterase-3 (PDE-3) inhibitor with inotropic and vasodilator properties. It is used in the short-term management of severe heart failure to improve cardiac output and reduce pulmonary capillary wedge pressure. The injection is supplied as a sterile, ready-to-use solution for intravenous administration under continuous medical monitoring.

Each ml contains:

• Milrinone Lactate IP
  (Equivalent to Milrinone IP) – strength as per label

• Water for Injection – q.s.

• Dosage Form: Injection

(Common strength: 1 mg/ml – can be adjusted as per your product)

MILICOR Injection is indicated for:

• Short-term treatment of acute decompensated heart failure

• Low cardiac output syndrome

• Congestive heart failure not responding to conventional therapy

• Cardiac support in intensive care settings

• For intravenous (IV) infusion only

• Administered under strict medical supervision with hemodynamic monitoring

• Dosage and duration as prescribed by a cardiologist or registered medical practitioner

• Inotropic and vasodilator action

• Improves cardiac contractility and reduces afterload

• Used in critical cardiac care

• Suitable for ICU and hospital use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Dosage Form: Injection

• Pack Type: Vial / ampoule

• Strength: As per label claim

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10 mg/ 10 ml

Enoxaparin Injection contains Enoxaparin Sodium, a low molecular weight heparin (LMWH) used as an anticoagulant. It works by inhibiting factor Xa and IIa (thrombin), thereby preventing the formation of blood clots. This injection is commonly used for the prevention and treatment of venous thromboembolism (VTE) and in certain cardiac conditions. It is supplied as a sterile, pre-filled injection for subcutaneous administration.

Each pre-filled syringe contains:

• Enoxaparin Sodium IP – Equivalent to Enoxaparin 40 mg

• Excipients – q.s.

• Dosage Form: Sterile injection for subcutaneous use

Enoxaparin Injection is indicated for:

• Prevention of deep vein thrombosis (DVT) in surgical or bedridden patients

• Treatment of acute deep vein thrombosis

• Treatment of pulmonary embolism

• Prevention of blood clots in acute coronary syndromes (ACS)

• Use in patients at risk of thromboembolic events

• For subcutaneous administration only

• Dosage and duration determined by a registered medical practitioner

• Typically injected into the abdomen or thigh, as per clinical guidance

• Low molecular weight heparin for anticoagulation

• Pre-filled syringe for accurate dosing and ease of administration

• Reduces risk of thromboembolic complications

• Suitable for hospital and home use under medical supervision

• Store at 2°C – 8°C (refrigerated)

• Protect from light

• Do not freeze

• Keep out of reach of children

• Strength: 40 mg / 0.4 ml

• Pack Type: Pre-filled syringe

• Pack Size: 1 syringe

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 40mg/0.4ml

Enoxaparin Injection contains Enoxaparin Sodium, a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat thromboembolic disorders. It works by inhibiting factor Xa and thrombin (factor IIa), thereby preventing blood clot formation. This formulation is supplied as a sterile pre-filled injection for subcutaneous use in patients requiring therapeutic anticoagulation, including those with acute coronary syndromes or venous thromboembolism.

Each pre-filled syringe contains:

• Enoxaparin Sodium IP – Equivalent to Enoxaparin 300 mg

• Excipients – q.s.

• Dosage Form: Sterile injection for subcutaneous use

Enoxaparin Injection is indicated for:

• Treatment of deep vein thrombosis (DVT)

• Treatment of pulmonary embolism (PE)

• Prevention of venous thromboembolism in high-risk patients

• Anticoagulation in acute coronary syndrome (ACS)

• Patients at risk of thromboembolic events due to immobilization or surgery

• For subcutaneous injection only

• Administered into the abdomen or thigh as per clinical guidance

• Dosage and treatment duration must be determined by a registered medical practitioner

• Pre-filled syringe allows accurate dosing

• Low molecular weight heparin for effective anticoagulation

• Pre-filled 3 ml syringe for ease of use

• Reduces risk of thromboembolic complications

• Suitable for hospital and home use under medical supervision

• Store at 2°C – 8°C (refrigerated)

• Protect from light

• Do not freeze

• Keep out of reach of children

• Strength: 300 mg / 3 ml

• Pack Type: Pre-filled syringe

• Pack Size: 1 syringe

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 300mg/3ml

CTD-M 6.25/25 Tablets are a fixed-dose combination antihypertensive medicine used for the management of high blood pressure (hypertension). It combines a beta-blocker with a thiazide-like diuretic, offering effective blood pressure control and reducing the risk of cardiovascular complications such as heart attack and stroke.

Each film-coated tablet contains:

• Metoprolol Succinate IP – 6.25 mg

• Chlorthalidone IP – 25 mg

• Excipients – q.s.

CTD-M 6.25/25 Tablets are indicated for:

• Treatment of essential hypertension

• Patients requiring combination therapy for better blood pressure control

• Reduction of cardiovascular risk associated with hypertension

• Dosage as prescribed by the physician

• Usually taken once daily, preferably in the morning

• Swallow whole with water; do not crush or chew

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

• Strip of 10 tablets

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 25 mg tablets

Atorvastatin Tablets IP are a lipid-lowering (statin) medication used to reduce elevated cholesterol and triglyceride levels in the blood. By inhibiting HMG-CoA reductase, atorvastatin helps lower LDL (bad cholesterol) and increase HDL (good cholesterol), thereby reducing the risk of cardiovascular events such as heart attack and stroke.

Each film-coated tablet contains:

• Atorvastatin Calcium IP equivalent to Atorvastatin (strength as specified)

• Excipients – q.s.

Available strengths commonly include: 10 mg, 20 mg, 40 mg, 80 mg

Atorvastatin Tablets IP are indicated for:

• Hypercholesterolemia

• Mixed dyslipidemia

• Hypertriglyceridemia

• Prevention of cardiovascular diseases

• Reduction of risk of myocardial infarction and stroke

• Management of lipid levels in patients with diabetes or coronary artery disease

• Dosage as prescribed by the physician

• Usually taken once daily, with or without food

• Regular monitoring of lipid levels is advised

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: Xtor-10

Eltrombopag Tablets 50 mg is an oral thrombopoietin receptor agonist used to increase platelet production in patients with certain platelet disorders. It works by stimulating platelet production in the bone marrow, thereby reducing the risk of bleeding. This medication should be used strictly under the supervision of a qualified physician or hematologist.

• Active Ingredient:
  Eltrombopag – 50 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablets

Eltrombopag Tablets are indicated for:

• Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

• Thrombocytopenia in patients with chronic hepatitis C (as prescribed)

• Severe aplastic anemia (as advised by a physician)

(Prescription medicine – hematology use only)

• Dosage as prescribed by the treating physician

• Tablets should be taken on an empty stomach or as directed

• Avoid taking with dairy products or mineral supplements unless advised

• Regular platelet count monitoring is required

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Liver function monitoring is required during therapy

• Use with caution in patients with hepatic impairment

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

• Manufactured in compliance with GMP standards

• Quality tested for safety, purity, and efficacy

• India

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 4x7 Tablets

Tacrogen 40 is a sterile, low molecular weight heparin (LMWH) injection containing Enoxaparin Sodium. It is used as an anticoagulant to prevent and treat blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Enoxaparin acts by inhibiting clotting factors in the blood, reducing the risk of thrombus formation. The injection is intended for subcutaneous or intravenous administration under medical supervision.

• Active Ingredient:
  Enoxaparin Sodium – 40 mg / 0.4 ml (equivalent to 4000 IU anti-Xa activity)

• Excipients:
  q.s.

• Dosage Form:
  Pre-filled sterile injection

Tacrogen 40 Enoxaparin Injection is indicated for:

• Prevention of deep vein thrombosis (DVT) in patients undergoing surgery

• Treatment of DVT and pulmonary embolism (PE)

• Prevention of clot formation in patients with unstable angina or non-ST segment elevation myocardial infarction (NSTEMI)

• Other conditions requiring anticoagulation as prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Administered subcutaneously or intravenously as directed by a physician

• Dose and frequency depend on patient condition, weight, and clinical indication

• Should be administered by trained healthcare professionals

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• For prescription use only

• Use with caution in patients with bleeding disorders or severe kidney impairment

• Not recommended during pregnancy unless prescribed

• Monitor platelet counts during prolonged therapy

• Pre-filled syringe / vial containing 40 mg (0.4 ml)

• Supplied with protective packaging

• Manufactured in compliance with IP and GMP standards

• Tested for sterility, potency, and safety

• India

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 40mg/0.4ml

Enoxaparin Injection IP 60 mg/0.6 ml is a sterile, low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat thromboembolic disorders. It works by inhibiting clotting factors, thereby reducing the formation of blood clots. This injection is intended for subcutaneous or intravenous administration under strict medical supervision in hospital and clinical settings.

• Active Ingredient:
  Enoxaparin Sodium – 60 mg / 0.6 ml (equivalent to 6000 IU anti-Xa activity)

• Excipients:
  q.s.

• Dosage Form:
  Pre-filled sterile injection

Enoxaparin Injection is indicated for:

• Prevention of deep vein thrombosis (DVT) in patients undergoing surgery

• Treatment of DVT and pulmonary embolism (PE)

• Prevention of clot formation in patients with unstable angina or non-ST segment elevation myocardial infarction (NSTEMI)

• Other conditions requiring anticoagulation as prescribed by a physician

(Prescription medicine – hospital and clinical use only)

• Administered subcutaneously or intravenously as directed by a physician

• Dose and frequency depend on patient weight, clinical condition, and indication

• To be administered only by trained healthcare professionals

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• For prescription use only

• Use with caution in patients with bleeding disorders, kidney impairment, or low platelet counts

• Not recommended during pregnancy unless prescribed

• Regular monitoring of platelet counts may be required

• Pre-filled syringe containing 60 mg / 0.6 ml

• Supplied with protective packaging

• Manufactured in compliance with IP and GMP standards

• Tested for sterility, potency, and safety

• India

Noradrenaline For Injection BP is a sterile, clear, colorless solution used as a potent vasopressor in critical care and emergency settings. It primarily stimulates alpha-adrenergic receptors, causing peripheral vasoconstriction and an increase in blood pressure. This injection is widely used in the management of acute hypotension and shock. Manufactured in accordance with British Pharmacopoeia (BP) standards, it ensures consistent quality, safety, and efficacy.

Each 1 ml contains:

• Noradrenaline (Norepinephrine) BP – 1 mg (as Noradrenaline bitartrate; strength may vary)

• Sodium Metabisulphite IP – as antioxidant

• Water for Injection IP – q.s.

• Treatment of acute hypotension

• Management of septic shock

• Cardiogenic and neurogenic shock

• Maintenance of blood pressure during anesthesia

• Critical care support in ICU and emergency units

• Administered by intravenous infusion only

• Must be diluted before use

• Dosage and infusion rate as prescribed by a qualified medical professional

• For hospital use only

• Powerful and fast-acting vasopressor

• BP grade pharmaceutical quality

• Sterile, pyrogen-free formulation

• Essential drug in ICU and emergency medicine

• Reliable control of systemic blood pressure

• Store in a cool place, below recommended temperature

• Protect from light

• Do not freeze

• Supplied in ampoules or vials

• Different pack sizes available

• Leak-proof and tamper-evident packaging

• To be used only under strict medical supervision

• Extravasation may cause tissue necrosis

• Continuous monitoring of blood pressure required

• Avoid prolonged use without proper assessment

• 24–36 months, as stated on the product label

Hospitals, ICUs, Emergency Departments, Operation Theatres, Ambulance Services

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 10x1 ml

Magnesium Sulphate for Injection BP

Magnesium Sulphate for Injection BP is a sterile aqueous preparation used in the treatment and prevention of magnesium deficiency and in various emergency and obstetric conditions. It acts as an electrolyte replenisher, anticonvulsant, and muscle relaxant.

This injection is widely used in hospitals, emergency units, and maternity care settings, particularly for the management of eclampsia and pre-eclampsia, as well as certain cardiac and neurological conditions.

Each mL contains:

• Magnesium Sulphate BP – 100 mg / 200 mg / 500 mg

• Water for Injection BP

(Common strengths: 25% or 50% w/v solution; exact strength available on request.)

• Treatment of hypomagnesemia

• Prevention and control of seizures in eclampsia and pre-eclampsia

• Management of torsades de pointes and certain cardiac arrhythmias

• Severe acute asthma (adjunct therapy)

• Electrolyte replacement in critical care patients

• Administered by intravenous (IV) or intramuscular (IM) injection

• Dosage and rate depend on indication and patient condition

• Continuous monitoring recommended during IV administration

• To be used under medical supervision only

• Glass ampoules or vials

• Available pack sizes: 2 mL / 5 mL / 10 mL / 20 mL

• Bulk and institutional supply available

• Store below 25°C

• Protect from light

• Do not freeze

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Typically 24–36 months

• Manufacturing Standards: WHO-GMP certified

• Usage Area: Hospitals, ICUs, maternity centers

• Prescription Status: Prescription drug (Rx)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 10x 1ml

Dobutamine Injection BP

Dobutamine For Injection BP is a cardioselective inotropic agent used to increase cardiac output in patients with heart failure and cardiogenic shock. It primarily stimulates β1-adrenergic receptors, improving myocardial contractility and stroke volume with minimal effect on heart rate.

Dobutamine is commonly used in critical care settings to support short-term management of severe heart failure, low cardiac output states, and cardiogenic shock.

Each ml contains:

• Dobutamine Hydrochloride BP/USP – 12.5 mg/ml (or as per formulation)

• Excipients: Sterile water for injection, suitable buffer

• Short-term management of acute heart failure

• Treatment of cardiogenic shock

• Support in low cardiac output states

• Used during cardiac surgery or in ICU to improve cardiac performance

• Administer via intravenous infusion only

• Dose is titrated based on patient response and clinical condition

• Continuous hemodynamic monitoring is recommended

• Use under strict medical supervision in ICU or emergency care

• Vials: 5 ml / 10 ml / 20 ml (concentration: 12.5 mg/ml)

• Sterile, ready-for-injection formulation

• Box packaging with product information leaflet

• Store at 2–8°C

• Protect from light and freezing

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10x1ml

Erythropoietin (PFS) 10,000 IU / 0.5–1 ml

Erythropoietin (EPO) PFS is a sterile, ready-to-use injectable formulation that stimulates red blood cell production. It is primarily used to treat anemia associated with chronic kidney disease, chemotherapy, or other conditions causing insufficient erythropoiesis. The pre-filled syringe ensures accurate dosing, convenience, and improved patient compliance.

• Erythropoietin (Recombinant Human EPO): 10,000 IU

• Excipients: Water for injection, sodium phosphate buffer, glycine, and BP/USP-grade stabilizers

Each pre-filled syringe delivers 10,000 IU in 0.5–1 ml depending on the manufacturer specification.

• Treatment of anemia associated with chronic kidney disease (CKD)

• Management of anemia in cancer patients receiving chemotherapy

• Prevention of anemia in patients undergoing major surgery

• Treatment of anemia due to bone marrow disorders or other chronic illnesses

• Administered via subcutaneous or intravenous injection as prescribed by a physician

• Dose and frequency depend on patient condition, hemoglobin levels, and response to therapy

• Use under supervision of a qualified healthcare professional

• Pre-filled syringe for accurate and convenient dosing

• Sterile and pyrogen-free formulation

• Recombinant human erythropoietin for effective red blood cell stimulation

• BP/USP-compliant and suitable for hospital and clinical use

• 0.5–1 ml PFS containing 10,000 IU EPO

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10000IU/0.5-1ml

Erythropoietin (Lyophilized) for Injection BP

Erythropoietin for Injection BP is a recombinant glycoprotein hormone that stimulates erythropoiesis (red blood cell production) in the bone marrow. It is used for treatment of anemia associated with chronic kidney disease, chemotherapy, and other medical conditions.

This lyophilized injectable formulation ensures stability and extended shelf life and is intended for intravenous (IV) or subcutaneous (SC) administration under specialist supervision.

Each vial contains:

• Erythropoietin BP – 2000 IU / 4000 IU / 10,000 IU

• Excipients: q.s. for sterile lyophilized injection

After reconstitution with sterile water, it is ready for subcutaneous or intravenous injection.

• Anemia due to Chronic Kidney Disease (CKD) – dialysis and non-dialysis patients

• Chemotherapy-Induced Anemia – in cancer patients undergoing treatment

• Perioperative Blood Management – to reduce the need for transfusions

• Anemia associated with HIV therapy

• Anemia in premature infants or neonates (under specialist supervision)

• Patients with bone marrow suppression

• Route: Subcutaneous (SC) or Intravenous (IV) injection

• Dose: Typically 50–150 IU/kg 2–3 times per week, adjusted based on hemoglobin response

• Monitoring: Hemoglobin levels, hematocrit, blood pressure, and iron status

• Precautions: Monitor for thromboembolic events and hypertension

⚠ Administer only under specialist supervision

• Available strengths: 2000 IU, 4000 IU, 10,000 IU vials

• Lyophilized powder for injection

• Hospital, dialysis, and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10000 IU

Streptokinase for Injection BP

Streptokinase for Injection BP is a thrombolytic (fibrinolytic) enzyme used to dissolve blood clots in acute thromboembolic conditions. It works by activating plasminogen to plasmin, which breaks down fibrin clots, restoring blood flow in affected vessels.

This sterile injectable formulation is intended for intravenous administration under specialist supervision and is widely used in cardiology, emergency medicine, and hospital settings for the management of acute myocardial infarction, pulmonary embolism, and deep vein thrombosis.

Each vial contains:

• Streptokinase BP – 750,000 IU / 1,500,000 IU

• Excipients: q.s. sterile water for injection (lyophilized powder)

After reconstitution, it is ready for intravenous infusion.

• Acute myocardial infarction (AMI) – to restore coronary blood flow

• Pulmonary embolism (PE) – massive or submassive

• Deep vein thrombosis (DVT) – selected cases to dissolve thrombi

• Arterial thromboembolism – including peripheral arterial occlusion

• Occluded intravenous catheters – as part of thrombolytic therapy (specialist use)

• Adjunct therapy in combination with anticoagulants under strict monitoring

• Route: Intravenous (IV) infusion

• Typical Adult Dose:

  • Acute MI: 1.5 million IU IV over 60 minutes

  • Pulmonary embolism / DVT: 250,000 IU IV bolus followed by 100,000 IU/hour infusion, adjusted per protocol

• Pediatric Dose: Weight-based, under specialist guidance

• Monitoring: Blood pressure, heart rate, coagulation parameters, and signs of bleeding

⚠ Administer only under specialist supervision

• Available strengths: 750,000 IU, 1,500,000 IU vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1.5 MIU

Rosuvastatin Tablets BP – 20 mg

Rosuvastatin Tablets BP is an oral lipid-lowering agent belonging to the statin (HMG-CoA reductase inhibitor) class, used for the management of hypercholesterolemia, mixed dyslipidemia, and prevention of cardiovascular diseases.

It works by inhibiting HMG-CoA reductase, reducing LDL cholesterol, total cholesterol, and triglycerides, while increasing HDL cholesterol. Rosuvastatin is particularly effective in patients with high cardiovascular risk, providing primary and secondary prevention of atherosclerotic cardiovascular events.

Each film-coated tablet contains:

• Rosuvastatin Calcium BP – 20 mg (equivalent to Rosuvastatin 20 mg)

• Excipients: q.s.

• Hypercholesterolemia

• Mixed dyslipidemia

• Familial hypercholesterolemia (heterozygous)

• Primary and secondary prevention of cardiovascular events

• Atherosclerotic cardiovascular disease (ASCVD) risk reduction

• High triglyceride management

• Adjunct to diet and lifestyle changes in lipid disorders

• Route: Oral

• Usual Dose: 5–40 mg once daily, adjusted by physician based on lipid profile and patient response

• Administration: Take any time of the day, with or without food

⚠ Monitor liver function tests regularly
⚠ Avoid in active liver disease or pregnancy
⚠ Caution in patients with renal impairment

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Losartan Tablets BP – 50 mg

Losartan Tablets BP is an oral antihypertensive agent belonging to the Angiotensin II Receptor Blocker (ARB) class. It works by blocking the action of angiotensin II, leading to vasodilation, reduced blood pressure, and decreased workload on the heart.

Losartan is commonly prescribed for hypertension, diabetic nephropathy, and cardiovascular risk reduction. It can be used as monotherapy or in combination with other antihypertensive agents, such as diuretics, to achieve optimal blood pressure control.

Each film-coated tablet contains:

• Losartan Potassium BP – 50 mg

• Excipients: q.s.

• Hypertension (high blood pressure)

• Diabetic nephropathy with type 2 diabetes

• Cardiovascular risk reduction in patients with left ventricular hypertrophy

• Heart failure management (as part of combination therapy)

• Prevention of stroke in high-risk patients

• Adjunct therapy for renal protection in diabetic patients

• Route: Oral

• Usual Dose: 50 mg once daily, may be increased to 100 mg daily depending on patient response

• Administration: Can be taken with or without food

⚠ Monitor renal function and potassium levels regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Avoid in pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Amlodipine + Atenolol Tablets BP – 5 mg + 50 mg

Amlodipine + Atenolol Tablets BP is an oral antihypertensive combination therapy used for the management of hypertension and angina pectoris.

• Amlodipine (5 mg): A calcium channel blocker (dihydropyridine class) that relaxes vascular smooth muscles, reduces peripheral vascular resistance, and lowers blood pressure.

• Atenolol (50 mg): A selective beta-1 adrenergic blocker that reduces heart rate and cardiac output, lowering blood pressure and controlling angina symptoms.

This combination provides dual action for better blood pressure control and is especially useful for patients who require both rate control and vasodilation.

Each film-coated tablet contains:

• Amlodipine Besylate BP – 5 mg

• Atenolol BP – 50 mg

• Excipients: q.s.

• Hypertension (high blood pressure)

• Chronic stable angina

• Control of heart rate in patients with cardiovascular risk

• Combination therapy when monotherapy is insufficient

• Reduction of cardiovascular morbidity in hypertensive patients

• Adjunct therapy in patients with ischemic heart disease

• Route: Oral

• Usual Dose: 1 tablet once daily, or as prescribed by the physician

• Administration: Take with or without food at the same time each day for consistent blood levels

⚠ Monitor blood pressure, heart rate, and renal function regularly
⚠ Caution in patients with heart failure, bradycardia, or severe hepatic impairment
⚠ Contraindicated in patients with sinus bradycardia, AV block, or cardiogenic shock

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Losartan + Hydrochlorothiazide Tablets BP – 50 mg + 12.5 mg

Losartan + Hydrochlorothiazide Tablets BP is an oral antihypertensive combination therapy used for the management of hypertension and associated cardiovascular risk.

• Losartan (50 mg): An angiotensin II receptor blocker (ARB) that relaxes blood vessels, reduces peripheral vascular resistance, and lowers blood pressure.

• Hydrochlorothiazide (12.5 mg): A thiazide diuretic that reduces blood volume by increasing urinary excretion of sodium and water, enhancing the antihypertensive effect of losartan.

This combination is effective for patients whose blood pressure is not adequately controlled with monotherapy, providing dual mechanism action for better cardiovascular protection.

Each film-coated tablet contains:

• Losartan Potassium BP – 50 mg

• Hydrochlorothiazide BP – 12.5 mg

• Excipients: q.s.

• Hypertension (high blood pressure)

• Reduction of cardiovascular morbidity in hypertensive patients

• Combination therapy when monotherapy is insufficient

• Management of edema associated with hypertension

• Adjunct therapy in patients with risk of heart failure or stroke

• Route: Oral

• Usual Dose: 1 tablet once daily, or as prescribed by the physician

• Administration: Take with or without food, preferably at the same time each day

⚠ Monitor blood pressure, renal function, and electrolytes regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Contraindicated in patients with hypersensitivity to sulfonamides or ARBs

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Telmisartan + Hydrochlorothiazide Tablets BP – 40 mg + 12.5 mg

Telmisartan + Hydrochlorothiazide Tablets BP is an oral antihypertensive combination therapy used for the management of hypertension and reduction of cardiovascular risk.

• Telmisartan (40 mg): An angiotensin II receptor blocker (ARB) that relaxes blood vessels, reduces peripheral vascular resistance, and lowers blood pressure.

• Hydrochlorothiazide (12.5 mg): A thiazide diuretic that promotes urinary excretion of sodium and water, reducing blood volume and enhancing the antihypertensive effect.

This combination is effective in patients not adequately controlled on monotherapy, providing dual-action blood pressure control and cardiovascular protection.

Each film-coated tablet contains:

• Telmisartan BP – 40 mg

• Hydrochlorothiazide BP – 12.5 mg

• Excipients: q.s.

• Hypertension (high blood pressure)

• Reduction of cardiovascular risk in hypertensive patients

• Combination therapy when monotherapy is insufficient

• Management of edema associated with hypertension

• Adjunct therapy in patients at risk of heart failure or stroke

• Route: Oral

• Usual Dose: 1 tablet once daily, or as prescribed by the physician

• Administration: Take with or without food, preferably at the same time each day

⚠ Monitor blood pressure, renal function, and electrolytes regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Contraindicated in patients with hypersensitivity to ARBs or sulfonamides

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Rosuvastatin + Aspirin + Clopidogrel Tablets BP – 10 mg + 75 mg + 75 mg

Rosuvastatin + Aspirin + Clopidogrel Tablets BP is a triple-combination oral therapy designed for cardiovascular risk reduction and secondary prevention of atherosclerotic events.

• Rosuvastatin (10 mg): A HMG-CoA reductase inhibitor (statin) that reduces LDL cholesterol, total cholesterol, and triglycerides, helping to slow atherosclerosis progression and lower cardiovascular risk.

• Aspirin (75 mg): An antiplatelet agent that inhibits platelet aggregation, preventing thrombus formation in high-risk cardiovascular patients.

• Clopidogrel (75 mg): An ADP receptor inhibitor (antiplatelet) that prevents platelet activation and aggregation, enhancing protection against myocardial infarction, stroke, and peripheral arterial disease.

This combination is ideal for patients at high cardiovascular risk or with a history of coronary artery disease, stroke, or peripheral artery disease, providing comprehensive lipid-lowering and antiplatelet therapy.

Each film-coated tablet contains:

• Rosuvastatin Calcium BP – 10 mg

• Aspirin BP – 75 mg

• Clopidogrel Bisulfate BP – 75 mg

• Excipients: q.s.

• Secondary prevention of cardiovascular events (MI, stroke, PAD)

• High-risk patients with dyslipidemia and atherosclerotic cardiovascular disease

• Post-angioplasty or stent placement

• Prevention of recurrent myocardial infarction or ischemic stroke

• Patients requiring combined lipid-lowering and antiplatelet therapy

• Route: Oral

• Usual Dose: 1 tablet once daily, or as prescribed by the physician

• Administration: Take with or after food to minimize gastric irritation

⚠ Monitor lipid profile, platelet function, and bleeding risk regularly
⚠ Caution in patients with peptic ulcer disease, bleeding disorders, or hepatic impairment
⚠ Contraindicated in active bleeding, hypersensitivity to any component, or pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: 120 tablets

NGMINE 250 Injection contains Bivalirudin, a direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention (PCI) and in patients with or at risk of heparin-induced thrombocytopenia (HIT). It provides predictable anticoagulation with a rapid onset and short duration of action. The injection is supplied as a sterile lyophilized powder for intravenous administration after reconstitution.

Each vial contains:

• Bivalirudin – 250 mg

• Sterile excipients – q.s.

• Dosage Form: Lyophilized powder for injection

NGMINE 250 Injection is indicated for:

• Anticoagulation in patients undergoing percutaneous coronary intervention (PCI)

• Patients with heparin-induced thrombocytopenia (HIT) undergoing PCI

• Prevention of thrombus formation during coronary procedures

• For intravenous (IV) use only

• To be reconstituted and diluted before administration

• Dosage and infusion rate as prescribed by a cardiologist or registered medical practitioner

• Direct thrombin inhibitor

• Predictable anticoagulant effect

• Rapid onset and short half-life

• Suitable for catheterization labs and critical care settings

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

• Strength: 250 mg

• Pack Type: Glass vial

• Pack Size: 1 vial

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 250mg

Chlorthalidone Tablets IP 6.25 mg are a thiazide-like diuretic antihypertensive medication used for the management of hypertension and certain conditions associated with fluid retention. At a low dose of 6.25 mg, chlorthalidone effectively helps reduce blood pressure while minimizing electrolyte imbalance and other dose-related side effects. The tablets are intended for oral administration under medical supervision.

Each uncoated/film-coated tablet contains:

• Chlorthalidone IP – 6.25 mg

• Excipients – q.s.

Chlorthalidone Tablets IP are indicated for:

• Treatment of hypertension

• Management of mild to moderate edema associated with cardiac, hepatic, or renal disorders

• Use alone or in combination with other antihypertensive agents

• Dosage as prescribed by the physician

• Usually taken once daily, preferably in the morning

• Tablet should be swallowed with water

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

• Available in blister strips

• Pack size: As per manufacturer (commonly strip of 10 tablets)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: CTD-6.25

Deferasirox Tablets 360 mg is an oral iron chelating agent used for the management of chronic iron overload. It works by binding excess iron in the body and facilitating its excretion, thereby helping to prevent iron-related organ damage. This medication is commonly prescribed for patients receiving long-term blood transfusions and should be used under the supervision of a qualified healthcare professional.

• Active Ingredient:
  Deferasirox – 360 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablets

Deferasirox Tablets are indicated for:

• Treatment of chronic iron overload due to frequent blood transfusions

• Iron overload in patients with thalassemia

• Other transfusion-dependent anemias as prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Dosage as prescribed by the physician based on iron levels

• Tablets should be taken as directed, usually once daily

• Do not crush or chew unless advised

• Regular monitoring of serum ferritin is recommended

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy and breastfeeding unless prescribed

• Use with caution in patients with kidney or liver impairment

• Regular monitoring of renal and hepatic function is required

• Strip or bottle pack (as available)

• Commercial hospital and pharmacy supply

• Manufactured in compliance with GMP guidelines

• Quality tested for safety, purity, and efficacy

• India

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10x10 tablets

Dalteparin Sodium Pre-Filled Syringe (PFS) 10,000 IU / 0.4–1 ml

Dalteparin Sodium is a low molecular weight heparin (LMWH) used as an anticoagulant for the prevention and treatment of thromboembolic disorders. This sterile pre-filled syringe (PFS) formulation provides accurate dosing and easy administration. Dalteparin inhibits blood clot formation by targeting clotting factors, making it ideal for deep vein thrombosis (DVT) prevention, pulmonary embolism (PE) treatment, and thromboprophylaxis in high-risk patients.

• Dalteparin Sodium: 10,000 IU anti-Xa activity

• Excipients: Water for injection, sodium chloride, and BP/USP-grade stabilizers

Each PFS delivers a precise dose in 0.4–1 ml, depending on manufacturer specifications.

• Prevention of deep vein thrombosis (DVT) in surgical or immobile patients

• Treatment of DVT with or without pulmonary embolism (PE)

• Prevention of clot formation in patients with unstable angina or myocardial infarction

• Thromboprophylaxis in high-risk medical or cancer patients

• Administered via subcutaneous injection only

• Dosage depends on patient weight, indication, and renal function

• Use under the supervision of a qualified healthcare professional

• Avoid intravenous administration unless specifically prescribed

• Pre-filled syringe ensures precise, ready-to-use dosing

• Sterile and pyrogen-free formulation

• Low molecular weight heparin with predictable anticoagulant effect

• BP/USP-compliant quality

• 0.4 ml to 1 ml PFS containing 10,000 IU dalteparin

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 0.4/1ml